Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Lung tissue-like culture system for bacterial pathogens to support antibiotic drug discovery (Efficacy and PK)
Third-party funded project
Project title Lung tissue-like culture system for bacterial pathogens to support antibiotic drug discovery (Efficacy and PK)
Principal Investigator(s) Jenal, Urs
Co-Investigator(s) Okujava, Rusudan
Organisation / Research unit Departement Biozentrum / Infection Biology
Department Departement Biozentrum,
Departement Biozentrum / Infection Biology
Project start 01.01.2021
Probable end 31.12.2022
Status Completed
Abstract

The focus of the Roche antibiotics discovery group is to identify broad-spectrum antibiotics with novel Mode of Action (MOA). A key indication is the treatment of Gram-negative, Difficult-to-treat (DTR), hospital-acquired infections;specifically, Hospital Acquired Pneumonia (HAP) / Ventilator Acquired Pneumonia (VAP), that are among the mostchallenging and life-threatening bacterial infections today and therefore, deserve a close attention (Petite andNguyen, 2018; Weiss. et al., 2019). In order to validate novel molecular entities identified in high throughput screens,Roche aim to establish an advanced cellular system that allows simulation of human lung infections, especiallyHAP/VAP.

Epithelix, a Geneva based company, has engineered an in vivo-like 3D cell culture model, MucilAir, mimicking lung(bronchial) airway system. Infection of the MucilAir system with P. aeruginosa led to a loss of the “epithelial barrier”function of the lung epithelium as observed during in vivo infections (Bertinetti C. et al, poster from Epithelix).

In this project, Roche propose to adapt the MucilAir system and establish infection conditions for other Gram-negative bacteria to be able to: assess potency and PK properties of prioritized hit series,

enable selection of clinical candidates improve the translation of in vitro data to human infections, thereby reducing the use of animal models (3R principle).

Similar interest for developing novel tools to support antibacterial discovery and development is a major goal of

Biozentrum University of Basel and ETH Zurich within the frame of National Center of Competence in Research (NCCR) AntiResist. Specifically, Prof. Christoph Dehio together with two other Biozentrum professors, Dirk Bumann and Urs Jenal have been awarded research funding to better understand pathogen physiology and heterogeneity in infected patients and development of in vitro systems that mimic relevant aspects of patient tissues.

This project will be funded by Roche Center of Excellence (CoE, Roche Pharma Sciences) as part of an umbrella initiative of lung models for infection diseases, immunology and safety. Such environment is an opportunity of crossfertilization for technical knowledge, as the above-mentioned 3D cell system could also be adapted to study viral lung infections, inflammatory processes of the lung and to address the safety aspects of the developmental compounds.

Direct collaborative connection between Roche and the research groups at Biozentrum and ETH Zurich will help to learn first-hand what type of progress is made in the field, with the possibility to gain access to patient sample analysis data and to the top advanced technologies available within the AntiResist initiative.

Financed by Private Sector / Industry

Cooperations ()

  ID Kreditinhaber Kooperationspartner Institution Laufzeit - von Laufzeit - bis
4639773  Jenal, Urs  Broz, Petr, Prof.  University of Lausanne  01.01.2021  31.12.2022 
4639774  Jenal, Urs  Hierlemann, Andreas, Prof.  ETH Zürich  01.01.2021  31.12.2022 
   

MCSS v5.8 PRO. 0.415 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
29/03/2024